Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. (Q38012488)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Jesús San Miguel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Maria-Victoria Mateos

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

24 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1075-1087

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

New insights into therapeutic targets in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The 26S proteasome: a molecular machine designed for controlled proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The structure of the mammalian 20S proteasome at 2.75 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Ubiquitin receptors and ERAD: a network of pathways to the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.691164

10.1517/13543784.2012.691164

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22621161%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference